CJC-1295 (No DAC) Purity: What 99% Actually Means on a COA

At a Glance: Deciphering CJC-1295 (No DAC) Analytical Certificates

A Certificate of Analysis (COA) is the primary document research laboratories rely on to confirm the identity, purity, and safety profile of synthetic peptides. However, a headline purity figure of 99% can be misleading if the underlying analytical methodology is not fully understood.

To properly evaluate a cjc-1295 (no dac) purity coa, investigators must distinguish between chromatographic purity (RP-HPLC peak area percentage) and net peptide content (the actual weight fraction of active peptide relative to counterions and moisture). Additionally, structural identity must be confirmed via mass spectrometry (LC-MS or ESI-MS), and biological contaminants must be ruled out through Limulus Amebocyte Lysate (LAL) endotoxin assays.

PX1 Research provides fully transparent, lot-matched documentation for every batch of research peptides, ensuring that cell culture and preclinical models yield reproducible, unconfounded data.

What Is CJC-1295 (No DAC) and How Does It Function in Preclinical Settings?

CJC-1295 (No DAC), also known as Modified GRF 1-29, is a synthetic 29-amino-acid analog of human Growth Hormone-Releasing Hormone (GHRH). By substituting specific amino acids at positions 2, 8, 15, and 27, the molecule demonstrates enhanced resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) compared to native GHRH 1-29.

In preclinical laboratory models, cjc 1295 functions as a selective GHRH receptor agonist. Studies indicate that it stimulates the anterior pituitary gland to release growth hormone in a pulsatile manner. Because this variant lacks the Drug Affinity Complex (DAC)—a maleimido derivative designed to bind serum albumin—it exhibits a significantly shorter biological half-life than its DAC-bound counterpart, making it a valuable tool for precise temporal control in endocrine research.

Researchers studying tissue regeneration, cellular repair, and metabolic signaling frequently utilize cjc no dac to evaluate downstream insulin-like growth factor 1 (IGF-1) cascades. When setting up in vitro or animal models, acquiring high-purity material is essential to avoid off-target receptor activation caused by peptide fragments or chemical residues. You can review full analytical specifications or order 10 mg vials of CJC-1295 (No DAC) directly from PX1 Research.

RP-HPLC Area Percent vs. Net Peptide Content: The 99% Fallacy

The most common misconception when reading a peptide COA is confusing Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) area percent with total mass purity. RP-HPLC measures UV absorbance at a specific wavelength (typically 214 nm or 220 nm) as chemical species elute from a non-polar stationary phase.

When a COA reports '99% purity by HPLC,' it means that 99% of the UV-absorbing material eluting during the chromatographic run corresponds to the target peptide peak. However, HPLC UV detectors do not detect non-chromatophoric substances such as residual moisture (water), inorganic salts, or organic counterions like trifluoroacetate (TFA).

During solid-phase peptide synthesis (SPPS), cleavage and deprotection steps utilize TFA. Unless subjected to extensive ion-exchange chromatography, the resulting peptide lyophilizate exists as a TFA salt. Counterions and bound water can constitute 10% to 30% of the total dry powder weight inside a vial. Consequently, a vial containing 10 mg of dry lyophilizate at 99% HPLC purity may only contain 7.5 mg to 8.5 mg of actual net peptide content. Laboratories calculating molar concentrations for in vitro assays must account for this difference to prevent experimental variability.

Mass Spectrometry (LC-MS / ESI-MS): Confirming Molecular Identity

While RP-HPLC establishes chromatographic homogeneity, it cannot confirm that the main peak is indeed CJC-1295 (No DAC). Two distinct peptides with similar hydrophobic profiles can co-elute under identical HPLC gradient conditions. Mass spectrometry is required to verify absolute molecular identity.

For CJC-1295 (No DAC) (chemical formula C152H252N44O42, theoretical monoisotopic mass ~3367.9 Da), Electrospray Ionization Mass Spectrometry (ESI-MS) or Liquid Chromatography-Mass Spectrometry (LC-MS) generates multi-charged ion species (e.g., [M+3H]3+, [M+4H]4+). The resulting mass spectrum confirms that the observed mass matches the calculated theoretical molecular weight within a strict tolerance window (typically ±1 Da).

A thorough mass spectrum analysis also detects truncated deletion sequences, incomplete side-chain deprotection, or oxidation artifacts (such as methionine oxidation) that might elute closely to the primary peak on an HPLC chromatogram. Without a clear MS spectrum accompanying the COA, chemical identity remains unverified.

Endotoxin Limits and LAL Testing: Why Biological Purity Matters

Chemical purity alone is insufficient for cell culture or preclinical animal studies. Bacterial endotoxins—lipopolysaccharides (LPS) shed from the outer membrane of Gram-negative bacteria—are potent pyrogens that skew biological data.

In cell culture assays, trace endotoxin contamination can trigger Toll-like receptor 4 (TLR4) signaling, inducing inflammatory cytokine expression (e.g., TNF-alpha, IL-6) and masking or altering the physiological response to GHRH receptor stimulation. In animal research models, high endotoxin levels cause fever, systemic inflammation, or septic shock.

Purity verification must include quantitative Limulus Amebocyte Lysate (LAL) testing or recombinant Factor C assays. PX1 Research enforces strict bioburden controls during synthesis and lyophilization, ensuring endotoxin levels remain well below established research thresholds (typically <0.01 EU/mg or <0.1 EU/mg depending on experimental requirements).

Why Two Vendors Claiming 99% Purity Ship Fundamentally Different Material

It is common in the research reagent market to see multiple vendors advertising '99% Pure CJC-1295 (No DAC),' yet researchers often observe inconsistent experimental results when switching suppliers. This disparity stems from contrasting analytical rigor and manufacturing standards.

Vendor A may rely on a single, non-validated HPLC run supplied by an overseas contract manufacturer. The run might utilize optimized integration parameters that smooth over shoulder peaks, omit MS identity confirmation entirely, and fail to test for TFA or endotoxins. The resulting material may consist of 70% net peptide, high TFA salt content, and trace bacterial contamination.

Vendor B (PX1 Research) subjects every production batch to independent third-party analysis. The COA provides peak-by-peak HPLC quantification, full ESI-MS spectra, counterion analysis, moisture determination, and LAL endotoxin quantification. Research teams purchasing from PX1 receive precise, lot-matched data that allows exact molar dilution without hidden variables.

Vendor Evaluation Criteria: Comparing Peptide Quality Metrics

When auditing peptide vendors for institutional procurement, research directors should evaluate suppliers against six objective quality parameters:

- **Purity Verification:** Does the vendor provide full-spectrum RP-HPLC chromatograms with baseline resolution and complete integration tables, or just a summarized percentage?

- **Identity Confirmation:** Is high-resolution ESI-MS or LC-MS data included for the exact lot number on the vial?

- **Counterion & Net Content Data:** Is TFA content or net peptide fraction quantified to allow precise stoichiometric calculations?

- **Endotoxin Compliance:** Is LAL endotoxin testing documented per batch with explicit EU/mg measurements?

- **Lot Traceability:** Does every vial feature a unique lot number that directly corresponds to an accessible, downloadable COA?

- **Fulfillment & Logistics:** Are compounds stored under climate-controlled conditions and dispatched rapidly from domestic facilities to prevent degradation?

Red Flags When Reviewing a CJC-1295 COA

To protect research integrity and budget, laboratories should flag and reject COAs that exhibit any of the following warning signs:

1. **Generic or Missing Lot Numbers:** A COA that lacks a specific lot matching the vial label is legally and scientifically meaningless.

2. **Cropped or Low-Resolution Chromatograms:** Vendors hiding impurity peaks often crop the baseline or lower the image resolution so integration lines cannot be inspected.

3. **Missing Analytical Parameters:** HPLC runs that omit column type, mobile phase composition, flow rate, or detection wavelength (nm) cannot be independently reproduced or verified.

4. **Absent Mass Spectrometry:** Claims of identity based solely on retention time without MS data represent a severe testing deficiency.

5. **Outdated Testing Dates:** COAs dated years prior to the purchase date indicate stale inventory or recycled testing documents.

6. **No Third-Party Laboratory Credentials:** Quality documentation should stem from accredited, independent analytical laboratories rather than internal marketing templates.

How to Request and Verify a Lot-Matched COA Before Purchasing

Legitimate research suppliers make lot-matched documentation readily accessible prior to acquisition. When vetting a supplier, request the specific COA for the current inventory batch rather than relying on a sample document.

Cross-reference the reported theoretical mass against known peptide sequences. For CJC-1295 (No DAC), verify that the observed ESI-MS mass envelope aligns with the 3367.9 Da monoisotopic mass. Check that the HPLC run shows sharp, symmetrical peaks without significant fronting or tailing, which indicates degradation or poor column selection.

At PX1 Research, analytical data is updated for every synthesis batch. Investigators can explore our peptide research library or review current batch reports directly on product pages before placing institutional orders.

Synergistic Peptide Research: Combining CJC-1295 (No DAC) with GHRPs

In preclinical endocrinology and cell signaling research, GHRH analogs are frequently studied in combination with Growth Hormone Secretagogue Receptor (GHSR) agonists. Because GHRH analogs and GHRPs operate through distinct, complementary intracellular pathways (PKA/cAMP vs. PLC/IP3/DAG), co-administration in animal models often demonstrates synergistic growth hormone release.

Researchers investigating dual-pathway secretagogue mechanisms frequently pair CJC-1295 (No DAC) with hexapeptides or heptapeptides such as Ipamorelin. Investigating the combined dynamics of a cjc ipamorelin protocol allows laboratories to map receptor crosstalk and downstream IGF-1 transcription.

To explore complementary secretagogues for comparative studies, review our Ipamorelin research peptide page, compare long-acting analogs via CJC-1295 with DAC, or browse our complete catalog of research peptides for institutional applications.

Ordering CJC-1295 (No DAC) from PX1 Research

PX1 Research is dedicated to supplying North American research institutions, university laboratories, and independent scientists with fully characterized, USA-synthesized research peptides. Every batch of CJC-1295 (No DAC) undergoes rigorous quality control, including RP-HPLC purity assessment, ESI-MS identity verification, and LAL endotoxin testing.

When you order from PX1, your material ships directly from our climate-controlled distribution hubs in California and Arizona. Orders placed before cutoff times Monday through Friday dispatch same-day via tracked domestic carrier services, ensuring minimal time in transit and preserving peptide integrity.

Each order arrives in lyophilized form inside sealed glass vials, accompanied by lot-matched documentation. High-volume research laboratories can also utilize the PX1 bulk peptide program for custom synthesis and bulk procurement options. Ready to source verified material for your laboratory? You can purchase CJC-1295 (No DAC) lyophilized powder today.